These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 33961287)

  • 1. Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders.
    Hopkins SC; Wilkinson S; Corriveau TJ; Nishikawa H; Nakamichi K; Loebel A; Koblan KS
    Clin Pharmacol Ther; 2021 Sep; 110(3):808-815. PubMed ID: 33961287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia.
    Wu J; Kwan AT; Rhee TG; Ho R; d'Andrea G; Martinotti G; Teopiz KM; Ceban F; McIntyre RS
    Expert Rev Clin Pharmacol; 2023; 16(11):1085-1092. PubMed ID: 37864424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain.
    Hopkins SC; Toongsuwan S; Corriveau TJ; Watanabe T; Tsushima Y; Asada T; Lew R; Shi L; Zann V; Snowden TJ; van der Graaf PH; Darpo B; Searle GE; Rabiner EA; Wilding I; Szabo ST; Galluppi GR; Koblan KS
    Clin Pharmacol Ther; 2024 Aug; 116(2):460-470. PubMed ID: 38822554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.
    Loebel A; Koblan KS; Tsai J; Deng L; Fava M; Kent J; Hopkins SC
    J Affect Disord; 2022 Jan; 296():549-558. PubMed ID: 34614447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D
    Düring SW; Nielsen MØ; Bak N; Glenthøj BY; Ebdrup BH
    Psychiatry Res; 2019 Apr; 274():58-65. PubMed ID: 30780063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
    Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relation between dopamine D
    Wulff S; Nielsen MØ; Rostrup E; Svarer C; Jensen LT; Pinborg L; Glenthøj BY
    Psychol Med; 2020 Jan; 50(2):220-228. PubMed ID: 30642415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.
    Kasper S; Tauscher J; Willeit M; Stamenkovic M; Neumeister A; Küfferle B; Barnas C; Stastny J; Praschak-Rieder N; Pezawas L; de Zwaan M; Quiner S; Pirker W; Asenbaum S; Podreka I; Brücke T
    World J Biol Psychiatry; 2002 Jul; 3(3):133-46. PubMed ID: 12478878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors.
    Hołuj M; Popik P; Nikiforuk A
    Behav Pharmacol; 2015 Dec; 26(8 Spec No):766-75. PubMed ID: 25769091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.